These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24690176)

  • 1. Monitoring of the serum proteome in Kawasaki disease patients before and after immunoglobulin therapy.
    Zhang L; Jia HL; Huang WM; Liu CW; Hua L; Liu TC; Mao LJ; Xu YF; Li W; Xia SL; Gan YY; Deng L; Zhang G
    Biochem Biophys Res Commun; 2014 Apr; 447(1):19-25. PubMed ID: 24690176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
    Sato S; Kawashima H; Kashiwagi Y; Hoshika A
    Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
    Abe J; Ebata R; Jibiki T; Yasukawa K; Saito H; Terai M
    J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
    Yoshimura K; Kimata T; Mine K; Uchiyama T; Tsuji S; Kaneko K
    J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
    Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
    Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease.
    Doi M; Takeda T; Sakurai Y; Kato J; Hayashi T; Fukuda K; Takase T; Shima M
    J Investig Allergol Clin Immunol; 2010; 20(5):413-8. PubMed ID: 20945608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease.
    Sakurai Y; Takatsuka H; Onaka M; Takada M; Nishino M
    Int Arch Allergy Immunol; 2014; 165(2):111-8. PubMed ID: 25401215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.
    Chang LS; Lo MH; Li SC; Yang MY; Hsieh KS; Kuo HC
    Oncotarget; 2017 Jan; 8(2):2044-2052. PubMed ID: 27893416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Tenascin-C as a Novel Predictor for Risk of Coronary Artery Lesion and Resistance to Intravenous Immunoglobulin in Kawasaki Disease　- A Multicenter Retrospective Study.
    Okuma Y; Suda K; Nakaoka H; Katsube Y; Mitani Y; Yoshikane Y; Ichida F; Matsushita T; Shichino H; Shiraishi I; Abe J; Hiroe M; Yoshida T; Imanaka-Yoshida K
    Circ J; 2016 Oct; 80(11):2376-2381. PubMed ID: 27746411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential protein analysis of serum exosomes post-intravenous immunoglobulin therapy in patients with Kawasaki disease.
    Zhang L; Song QF; Jin JJ; Huang P; Wang ZP; Xie XF; Gu XQ; Gao XJ; Jia HL
    Cardiol Young; 2017 Nov; 27(9):1786-1796. PubMed ID: 28803590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of sICAM-1 in children with intravenous immunoglobulin-resistant Kawasaki disease].
    Liu F; Ding Y; Yin W
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Dec; 15(12):1109-12. PubMed ID: 24342209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL; Zhao SL
    Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
    J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
    Yanagimoto K; Nomura Y; Masuda K; Hirabayashi M; Morita Y; Yoshishige M; Ueno K; Eguchi T; Kawano Y
    Int Arch Allergy Immunol; 2014; 164(2):83-8. PubMed ID: 24903098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
    Simonini G; Masi L; Giani T; Piscitelli E; Cimaz R; Vierucci S; Brandi ML; Falcini F
    J Rheumatol; 2005 Nov; 32(11):2233-8. PubMed ID: 16265708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
    Wittkowski H; Hirono K; Ichida F; Vogl T; Ye F; Yanlin X; Saito K; Uese K; Miyawaki T; Viemann D; Roth J; Foell D
    Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.